149 related articles for article (PubMed ID: 3632919)
1. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte adherence inhibition, natural killer cell activity, gamma-interferon production capacity and phytohemagglutinin response in patients treated with recombinant leukocyte A interferon.
Tank B; Bijma AM; Marquet RL; Eggermont AM; Weimar W; Jeekel J; Westbroek DL
Oncology; 1985; 42(3):157-63. PubMed ID: 3923413
[TBL] [Abstract][Full Text] [Related]
3. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
4. Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity.
Tank B; Marquet RL; Weimar W; Westbroek DL
Br J Cancer; 1984 Aug; 50(2):227-30. PubMed ID: 6466539
[No Abstract] [Full Text] [Related]
5. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
6. Recombinant leukocyte A interferon as single agent therapy or in combination with cimetidine in patients with advanced colo-rectal carcinoma. A phase II investigation.
Flodgren P; Hugander A; Sjögren HO
Acta Radiol Oncol; 1985; 24(1):25-34. PubMed ID: 2984899
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment.
Eggermont AM; Weimar W; Marquet RL; Laméris JD; Jeekel J
Cancer Treat Rep; 1985 Feb; 69(2):185-7. PubMed ID: 3882227
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
Hersey P; Hasic E; MacDonald M; Edwards A; Spurling A; Coates AS; Milton GW; McCarthy WH
Br J Cancer; 1985 Jun; 51(6):815-26. PubMed ID: 3873953
[TBL] [Abstract][Full Text] [Related]
9. Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.
Clark PI; Slevin ML; Reznek RH; Niederle N; Kurschel E; Lundell G; Cedermark B; Fallenius A; Blomgren H; Ohman U
Int J Colorectal Dis; 1987 Feb; 2(1):26-9. PubMed ID: 3598328
[TBL] [Abstract][Full Text] [Related]
10. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.
Krown SE; Mintzer D; Cunningham-Rundles S; Niedzwiecki D; Krim M; Einzig AI; Gabrilove JL; Shurgot B; Gessula J
Cancer Treat Rep; 1987 Jan; 71(1):39-45. PubMed ID: 3791267
[TBL] [Abstract][Full Text] [Related]
11. Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.
Triozzi PL; Kenney P; Young D; Rinehart JJ
Cancer Treat Rep; 1987 Oct; 71(10):983-4. PubMed ID: 3308083
[No Abstract] [Full Text] [Related]
12. A Phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer.
Silgals RM; Ahlgren JD; Neefe JR; Rothman J; Rudnick S; Galicky FP; Schein PS
Cancer; 1984 Nov; 54(10):2257-61. PubMed ID: 6488145
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
15. High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II study.
Lundell G; Blomgren H; Cedermark B; Silfverswärd C; Theve T; Ohman U
Radiother Oncol; 1984 Mar; 1(4):325-32. PubMed ID: 6505269
[TBL] [Abstract][Full Text] [Related]
16. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of recombinant beta interferon in advanced colorectal cancer.
Lillis PK; Brown TD; Beougher K; Koeller J; Marcus SG; Von Hoff DD
Cancer Treat Rep; 1987 Oct; 71(10):965-7. PubMed ID: 3308080
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
19. [Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
Niederle N; Kurschel E; Schmidt CG
Dtsch Med Wochenschr; 1984 May; 109(20):779-82. PubMed ID: 6723531
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
